Entera Bio Ltd. Ordinary Shares (ENTX)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Entera Bio is a clinical-stage biotechnology company with 20 employees, not an operating business in the Graham sense. Its reported revenue was $42,000 in fiscal 2025 (year ended 2025-12-31), down from $181,000 in fiscal 2024, while net loss widened to $11.4 million from $9.5 million. In fiscal Q2 2026 (quarter ended 2026-06-30), the filed net loss was $7.3 million, far larger than the $2.7 million loss in fiscal Q2 2025 (quarter ended 2025-06-30). The company burns cash: trailing free cash flow was negative $11.0 million, a negative 16.5% yield on the $66.4 million market value at the 2026-10-13 close. The balance sheet carries little debt (D/E 0.06), which is a small positive, but Altman Z-score of -5.92 signals financial distress, and Piotroski F-score 3/9 is weak. Price is $2.49. FairStock's P/B is 16.60, P/E is -7.11, ROE is -138.92%, and ROCE is -45.98%; the stock is not cheap on assets or earnings. The Lynch category is 'none' because it lost money in each of the last four years. Any value here rests on EB613 and EB612 succeeding in clinical trials. I see no moat, no stable earnings, no dividend, and no margin of safety in current numbers. It is a speculative biotech option, not a Graham bargain.

In plain English: Entera Bio is a small drug company working on pills for bone and hormone problems. It has almost no sales and is losing money, and the losses are getting bigger. At $2.49 a share, the price looks expensive compared with its tiny business and assets, so the numbers do not show a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer